Webinar Series: Predictive Assays and Clinically-Relevant Biomarkers for Parkinson’s Disease Drug Discovery

Neurodegenerative disorders such as Parkinson’s disease (PD) and Alzheimer’s disease (AD) represent an ever-increasing unmet medical need.

In two-part webinar series, we showcase in vitro phenotypic assays to identify new disease targets and novel drug compounds and highlight the development of biomarkers for disease modifying and symptom management therapies in in vivo models.

Jigsaw puzzle neurons
In vitro

In Vitro Phenotypic Assays as Predictive Tools to Drive Parkinson’s Disease Drug Discovery


The discovery and validation of novel targets are essential to fuel a healthy drug pipeline, and in vitro phenotypic assays are instrumental for delivering valid targets and promising lead molecules.

View this webinar to learn more about our in vitro assay capabilities performed in clinically relevant cell models, where we’ll highlight key endpoints for neurodegenerative diseases such as a-synuclein aggregation, Ab toxicity and autophagy/mitophagy readouts.

 

View The Replay

 

Grey mouse

A Comprehensive Review of Biomarker Endpoints In In Vivo Models of Parkinson’s Disease


Therapeutic approaches for Parkinson’s disease are either focused on disease modification (a-synuclein or MPTP models) or symptom management (haloperidol or 6-OHDA models). Our scientists have validated available PD models for changes in fine motor skills, L-dopa-induced dyskinesias, drug-induced jaw movements, and non-motor endpoints such as cognition, constipation, and EDS. Additionally, we have also tested dopamine and other neurotransmitter levels in brain compartments of rodent and large animal models via microdialysis sampling.

View this webinar for a comprehensive review of the validation data from established and novel animal models of Parkinson’s disease.

 

View The Replay